<?xml version="1.0" encoding="UTF-8"?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="section">
    <meta>
      <identification source="#ct-legislature">
        <FRBRWork>
          <FRBRthis value="/akn/us-ct/act/cgs/sec-17a-673a"/>
          <FRBRuri value="/akn/us-ct/act/cgs/sec-17a-673a"/>
          <FRBRdate date="2025-12-31" name="enacted"/>
          <FRBRauthor href="#ct-legislature"/>
          <FRBRcountry value="us-ct"/>
          <FRBRnumber value="17a-673a"/>
          <FRBRname value="CGS"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/akn/us-ct/act/cgs/sec-17a-673a/eng@2025-12-31"/>
          <FRBRuri value="/akn/us-ct/act/cgs/sec-17a-673a/eng@2025-12-31"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#arch"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/akn/us-ct/act/cgs/sec-17a-673a/eng@2025-12-31/main.xml"/>
          <FRBRuri value="/akn/us-ct/act/cgs/sec-17a-673a/eng@2025-12-31/main.xml"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#arch"/>
        </FRBRManifestation>
      </identification>
      <references source="#arch">
        <TLCOrganization eId="arch" href="https://cosilico.ai" showAs="Cosilico Arch"/>
        <TLCOrganization eId="ct-legislature" href="https://www.cga.ct.gov" showAs="Connecticut General Assembly"/>
      </references>
    </meta>
    <body>
      <chapter eId="chp_319j">
        <num>319j</num>
        <heading>Health Care For Uninsured Children</heading>
        <section eId="sec_17a_673a">
          <num>17a-673a</num>
          <heading>Opioid use disorder treatment program requirements</heading>
          <subsection eId="17a_673a__subsec_a">
            <num>(a)</num>
            <content>
              <p>As used in this section:</p>
            </content>
            <paragraph eId="17a_673a__subsec_a__subsec_1">
              <num>(1)</num>
              <content>
                <p>“Treatment program” means a program operated by the Department of Mental Health and Addiction Services or approved by the Commissioner of Mental Health and Addiction Services for treatment of the physical and psychological effects of drug dependency or for the detoxification of a drug-dependent person, as defined in section17a-680;</p>
              </content>
            </paragraph>
            <paragraph eId="17a_673a__subsec_a__subsec_2">
              <num>(2)</num>
              <content>
                <p>“Opioid use disorder” means a medical condition characterized by a problematic pattern of opioid use and misuse leading to clinically significant impairment or distress; and</p>
              </content>
            </paragraph>
            <paragraph eId="17a_673a__subsec_a__subsec_3">
              <num>(3)</num>
              <content>
                <p>“Opioid antagonist” means naloxone hydrochloride or any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose.</p>
              </content>
            </paragraph>
          </subsection>
          <subsection eId="17a_673a__subsec_b">
            <num>(b)</num>
            <content>
              <p>A treatment program that provides treatment or detoxification services to any person with an opioid use disorder shall</p>
            </content>
            <paragraph eId="17a_673a__subsec_b__subsec_1">
              <num>(1)</num>
              <content>
                <p>educate such person regarding opioid antagonists and the administration thereof at the time such person is admitted to or first receives services from such program,</p>
              </content>
            </paragraph>
            <paragraph eId="17a_673a__subsec_b__subsec_2">
              <num>(2)</num>
              <content>
                <p>offer education regarding opioid antagonists and the administration thereof to the relatives and significant other of such person if the relatives and significant other have been identified by such person, and</p>
              </content>
            </paragraph>
            <paragraph eId="17a_673a__subsec_b__subsec_3">
              <num>(3)</num>
              <content>
                <p>if there is a prescribing practitioner affiliated with such program who determines that such person would benefit from access to an opioid antagonist, issue a prescription for or deliver to such person at least one dose of an opioid antagonist at the time such person is admitted to or first receives treatment services from such program.
(Return to ChapterTable of Contents)(Return toList of Chapters)(Return toList of Titles)</p>
              </content>
            </paragraph>
          </subsection>
        </section>
      </chapter>
    </body>
  </act>
</akomaNtoso>